0001140361-18-021345.txt : 20180502 0001140361-18-021345.hdr.sgml : 20180502 20180502182628 ACCESSION NUMBER: 0001140361-18-021345 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180501 FILED AS OF DATE: 20180502 DATE AS OF CHANGE: 20180502 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: RAY DEBANJAN CENTRAL INDEX KEY: 0001706863 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37587 FILM NUMBER: 18801150 MAIL ADDRESS: STREET 1: C/O CYTOMX THERAPEUTICS, INC. STREET 2: 151 OYSTER POINT BLVD, SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CytomX Therapeutics, Inc. CENTRAL INDEX KEY: 0001501989 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273521219 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650.515.3185 MAIL ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc1.xml FORM 4 X0306 4 2018-05-01 0 0001501989 CytomX Therapeutics, Inc. CTMX 0001706863 RAY DEBANJAN C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., SUITE 400 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Financial Officer Common Stock 2018-05-01 4 M 0 3000 1.2599 A 7741 D Common Stock 2018-05-01 4 S 0 3000 26.5207 D 4741 D Stock Option (Right to Buy) 1.2599 2018-05-01 4 M 0 3000 0.00 D 2023-12-10 Common Stock 3000 8710 D The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. This transaction was executed in multiple trades in prices ranging from $26.22 to $26.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. 100% of the shares subject to the option are fully vested and exercisable. /s/ Debanjan Ray 2018-05-03